Listen

Add to my selection

VABYSMO (faricimab)

Medicine - Posted on Feb 22 2023

Active substance (DCI)

faricimab

history (2)

1/18/23

VABYSMO (faricimab) - Diabetic macular oedema (DME)

New indication. Key points Favourable opinion for reimbursement only in “the treatment of adult patients with visual impairm...

CAV :
54321

icône flèche
1/18/23

VABYSMO (faricimab) - Neovascular (wet) retrofoveal age-related macular degeneration (AMD)

New indication. Key points Favourable opinion for reimbursement “the treatment of neovascular (wet) retrofoveal age-related ...

CAV :
54321

icône flèche

Technical information

ATC code

S01LA9

Manufacturer

ROCHE

Presentation

VABYSMO 120 mg/mL, solution injectable
1 flacon contenant 0,24 mL de solution (CIP : 34009 302 625 9 7)

All our publications

Diabetes mellitus